1. Introduction {#sec1}
===============

A Gram-negative bacterium, *Pseudomonas aeruginosa*has emerged as a prevalent nosocomial pathogen not only for hospital-acquired \[[@B59]\] and medical device-related infections \[[@B12], [@B19]\], but also for burn \[[@B5]\] and war-wound infections \[[@B8]\]. For such a wide spectrum of infections, the molecular pathogenesis is still incompletely understood. Mechanisms underlying the wide range of infections may entail the bacterial stress responses that help the microorganism to fit in new environments. The stress responses encompass the production of outer membrane vesicles (OMVs) in a process of vesiculation that occurs during all phases of growth of Gram-negative bacteria \[[@B4], [@B51]\]. OMVs also play a role in the pathogenesis as *P. aeruginosa*OMVs deliver multiple enzymes and virulence factors into the host cells \[[@B6]\]. Furthermore, bacteria produce OMVs in response to environmental and cellular stress factors \[[@B39]--[@B70]\], as vesiculation appears to increase survival of bacteria over stress. Environmental stress constitutes antibiotic treatments that have been found to affect vesiculation. Treatment of *Shigella dysenteriae* with mitomycin C, which activates the SOS response \[[@B41], [@B55]\], led to the increased level of Shiga toxin-associated OMV production \[[@B22]\] and toxin production \[[@B75]\]. Such stress-induced vesiculation seems to enhance survival, since the under-vesiculating mutants of *Escherichia coli*succumbed, whereas the overvesiculating mutants appeared more viable, when they were challenged with lethal envelope stressors \[[@B53]\]. With vesiculation identified as a bacterial stress response to environmental stimuli such as antibiotics, antibacterial treatment may aggravate the infections. Therefore, while mechanisms underlying vesiculation resulting from stress responses, especially the antimicrobial-triggered SOS response, remain poorly understood, it is imperative to investigate the connection so that effective intervention can be developed.

The SOS response \[[@B76]\] is a transcriptional response, in which LexA controls at least 40 SOS genes in *E. coli*\[[@B13]--[@B40]\] and 15 in *P. aeruginosa* \[[@B10]\]. SOS is triggered when bacteria are treated with DNA damage antibiotics, such as the quinolone antibiotic ciprofloxacin used in this work. The quinolone antibiotics target the type II topoisomerases including DNA gyrase (topoisomerase II) and topoisomerase IV \[[@B21]\]. These enzymes play an essential role in controlling superhelix density of chromosomal DNA to facilitate replication, recombination, repair, and transcription \[[@B21], [@B29]\]. Inhibiting these enzymes by ciprofloxacin leads to DNA strand breaks, the SOS signals. The mechanisms of the SOS response in*P. aeruginosa* and*E. coli* share the following steps ([Figure 1](#fig1){ref-type="fig"}). In the absence of the SOS signals, LexA blocks the transcription of the SOS genes \[[@B76]\]. When the SOS signals are generated during replication inhibition, RecA coprotease senses the signals and binds to the single-stranded DNAs to assume an active conformation \[[@B66]\]. Activated RecA stimulates the autocatalytic cleavage of LexA \[[@B47]\]. Consequently, LexA repression of the SOS genes is dismissed by this cleavage. Such derepression induces the SOS genes, leading to activation of the SOS response. One of them, *sulA,* is induced to inhibit and delay cell division transiently, resulting in cell filamentation, a sign of the SOS response, until DNA damage is ameliorated by the SOS proteins. The SOS proteins are involved in chromosome recombination, replication, repair, and segregation \[[@B15], [@B67]\]. As cell division is affected during SOS and is involved in OMV biogenesis \[[@B18]\], vesiculation may be linked to SOS. With antimicrobial agents inducing SOS and vesiculation, this link is quite likely as both SOS and vesiculation enhance bacterial survival \[[@B53], [@B20]\]. The purpose of this study is to investigate this link with multiple analyses.

2. Materials and Methods {#sec2}
========================

2.1. Bacterial Strains, Media, and Chemicals {#sec2.1}
--------------------------------------------

*P. aeruginosa* PAO1 was obtained from the *Pseudomonas* Genetic Stock Center (strain PAO0001). The LexA noncleavable (*lexAN*) strain, gratefully from Dr. Floyd E. Romesberg, was constructed by the replacement of the catalytic serine of LexA with alanine as described in \[[@B10]\] so that the SOS regulon is repressed by *lexAN* in the presence of DNA damage. All the strains were grown at 37°C in Luria-Bertani (LB, purchased from Fisher Scientific) with 1-*μ*g/mL ciprofloxacin (Sigma-Aldrich, minimal inhibitory concentrations or MIC = 0.125 *μ*g/mL) as described before \[[@B10]\]. Experiments started with overnight cultures derived from the one-day-old single colonies grown on LB plates; experiments with colonies older than 3 days might not be reproducible.

2.2. Microscopic Analysis {#sec2.2}
-------------------------

Microscopy and measurement of cell length were performed as described \[[@B28], [@B78]\]. Briefly, the log-phase cells were fixed as described \[[@B28]\] and examined under a microscope (ZESS Axioshop 2 plus) equipped with CCD and computerized image analysis. The cell length was measured with NIH Image J. Significance levels (probability *P*values) in mean cell length were determined from a two-tailed Student\'s *t*-test.

2.3. OMV Extraction {#sec2.3}
-------------------

Overnight cultures were diluted to the OD~600 nm~ of 0.01 with 7 mL LB in a 25-mL flat-bottom glass tube. The subcultures were grown in a shaker at 37°C at the 250-rpm speed for 8 hrs. After the first two hours, ciprofloxacin was added to the subcultures to the final concentration of 1 *μ*g/mL. OMVs were isolated by a standard method \[[@B1]\] with slight modifications. The cells in the subcultures were removed first by centrifugation at 10,000 rpm (12,000 g) for 10 minutes at 4°C and second by filtering the supernatant through a 0.2-*μ*m filter. The filtered supernatant (6 mL) was ultracentrifuged in a fixed angle rotor (Ti-1270) for 3 hours at 4°C for 33,000 rpm (100,000 g). The supernatant was discarded, and the pellet was resuspended in 50 *μ*L of phosphate buffered saline (PBS) by pipetting rather than by vortexing. The OMV samples could be stored at 4°C for 1 day for the macrophage assay and 3 days for proteomic analysis without losing activity.

2.4. Lipid Extraction and Quantification {#sec2.4}
----------------------------------------

The method was adopted from a protocol published previously \[[@B2]\] with slight modifications. The procedures included an extraction of the lipids with a mixture of methanol, chloroform, and water in a ratio of 2 : 2 : 0.8 (v/v). The OMV pellet collected after ultracentrifugation of the 7-mL cell-free culture was resuspended in 80 *μ*L water in an eppendorf tube and then, to the OMV suspension, 200 *μ*L methanol, and 200 *μ*L chloroform were added and mixed. To the cell pellet, water was added to the final volume of 500 *μ*L, and the cells were resuspended completely by vigorous vortexing. Then, an 80-*μ*L volume of cell suspension was transferred to an effendorf tube and mixed with 200 *μ*L methanol and 200 *μ*L chloroform. After a 10-min vortexing, the sample was centrifuged for 10 min at 13,000 rpm at 4°C. The chloroform layer was transferred completely by gently inserting a pipette through the water-methanol phase and the interphase down to the bottom of the tube. To the tube containing the aquatic phases, 100 *μ*L chloroform and 80 *μ*L water were added and mixed by a vortexing. Centrifugation and chloroform layer transfer were repeated as above. The two fractions of chloroform layers were pooled; effort should be made to avoid losing any volumes of these fractions. For quantification, an empty eppendorf tube had been weighed, and then, the chloroform fractions were transferred to it and evaporated to dryness in a speed vac. The dry lipids were weighed, and the net weight was acquired by subtracting the tube weight.

2.5. Transmission Electron Microscope (TEM) {#sec2.5}
-------------------------------------------

TEM was conducted according to a standard protocol \[[@B44]\] with modifications. A 10-*μ*L volume of the OMV sample was placed on the lacey carbon film on 300-mesh copper grids. The grids were incubated at 25°C overnight. Then, they were negatively stained by 1% uranyl acetate (w/v, Sigma) for 20 seconds, washed three times with water, and air-dried. OMVs were examined on an Analytical Electron Microscope (JEOL JEM-2010F) with a Schottky field emission electron source. TEM was operated at accelerating voltage of 200 kV, with resolution at 0.1 nm lattice with 0.19 nm point-to-point, with magnification range from 2,0000x to 1,500,000x, with spot sizes of 2\~5 nm at TEM mode, with EDS/NBD/CBD of 0.5\~2.4 nm, and with specimen tilt at ±25 degrees (X, Y). Images were taken with a camera length of 80\~2,000 mm and objective lens of Cs 0.5 mm and Cc 1.1 mm. For each sample, 5--10 images were recorded, and the diameter of each OMV was measured and compared for statistical significance as above.

2.6. Macrophage Cytotoxicity and MTT Assay {#sec2.6}
------------------------------------------

The indicated equal amount of OMVs ([Figure 4](#fig4){ref-type="fig"}) determined according to the OMV protein assay were suspended in DMEM medium and added into a 96-well plate which had been seeded with murine macrophage J774 cells (2 × 10^5^/well). The plate was incubated at 37°C with 5% CO~2~ (v/v). The cytotoxicity was examined in the macrophage cytotoxicity assays as described previously \[[@B73]\] with modifications. The seeded macrophage was incubated with OMVs at the indicated concentrations. First, macrophage morphology was examined under a phase-contrast microscope with a 40-x lens \[VZEISS AXIOVERT-200 with AXIOCAM camera equipped with CCD and computerized image analysis\] after 0.5, 1, 2, 4, and 24 h. Approximately 10 fields were examined for each of duplicate wells. Second, the commercial kit (cyto 96 nonradioactive cytotoxicity kits from Promega) was used to measure OMV cytotoxicity to macrophage. The concept of this kit is to measure a stable cytosolic enzyme lactate dehydrogenase (LDH), which is released when macrophage cells are lysed. The released LDH then reacts with NAD, and protons are donated to NAD from LDH. The reducing NADH then reacts with MTT \[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide\] and formazan (red) forms. By measuring the optical density of formazan at the wavelength of 490-nm, the cytotoxicity was quantified. The cytotoxicity is defined as the percentage of OMV-inflicted LDH release in contrast to the sum of detergent-lysed maximal release (positive control) and spontaneous release (negative control). The assay was carried out by following the manufacturer\'s protocol. The experiment wells were assembled to contain the 20-*μ*L OMV sample, the 80-*μ*L medium (DMEM plus 10% FBS, v/v and the 2 × 10^5^target cells J774 cells), and the OMV effectors. The following control wells were arranged. The wells for effecter spontaneous LDH release contained medium and OMVs. The wells for target cell spontaneous LDH release included only target cells (macrophage) and medium. The wells for target cell maximum LDH release carried medium, target cells, and the Lysis Solution. A 10-*μ*L volume of the Lysis Solution (10x) per 100 *μ*L of culture medium was added, and the mixture was incubated for 45 minutes before the supernatant was harvested. The wells for volume correction control contained only medium and lysis solution. The wells for culture medium background were used to correct phenol red and LDH activity that might be present in serum-containing culture medium. The 96-well plate then was incubated at 37°C with 5% CO~2~ (v/v) for 4 hours. After incubation, the supernatant (40--50 *μ*L) from each well (except for the Maximal LDH release control) was transferred into a well in a new 96-well plate and mixed with the same volume of substrate (tetrazolium salt, light-sensitive, so operate in dark). The 96-wells plate was incubated in the dark for 30 minutes at the room temperatures, and the reaction was terminated by adding the stop solution. The optical density was measured at the 490-nm wavelength.

2.7. OMV Proteomic Analysis {#sec2.7}
---------------------------

The proteomic analysis was performed by following a standard method \[[@B80]\] with slight modifications. Specifically, the OMV proteins were fractionated by SDS-PAGE \[[@B65]\] (10%, w/v) and stained by Coomassie blue. The lanes in replicates containing the proteins were cut out, sliced into pieces (1 × 1 mm), and placed into Eppendorf tubes. The slices were subjected to *in vitro* proteolysis by trypsin as follows. The first step was SDS removal from the gel slices. A 100-*μ*L volume of 25 mM NH~4~HCO~3~/50% acetonitrile (v/v, Fisher) was added to cover the gel slice. The mixture was vortexed for 10 minutes, and the supernatant was discarded. These steps were repeated until the gel became colorless. Acetonitrile (100%, v/v) was added to cover the gel slices, and the mixtures were incubated for a few minutes at room temperatures until the gel slices shrank and turned white. Acetonitrile in the gel slices was removed by spinning in a speed vacuum at room temperatures to complete dryness. The second step was reduction, alkylation, and proteolysis. For rehydration of the gel slices, an approximate 50-*μ*L volume of 10-mM DTT (Sigma) in 25-mM NH~4~HCO~3~ was added to each tube to cover the gel slices followed by vortexing and brief spinning. The reagents were allowed to react with gel pieces at 56°C for 60 minutes, and the supernatant was discarded. A 40-*μ*L volume of 55 mM iodoacetamide (Sigma) was added to the gel pieces, and the mixture was vortexed and then centrifuged briefly. The reaction was incubated in the dark for 30 min, and the supernatant was removed. The gels were washed in 100 *μ*L (or enough to cover the gels) of 25-mM NH~4~HCO~3~/50% acetonitrile (v/v) followed by vortex and centrifugation for 5 min. A 200-*μ*L volume of acetonitrile (100%, v/v) was added and removed as above. Trypsin (3 mg/mL, Promega) was added to just barely cover the gel pieces, and after a brief spinning, the mixture was incubated at 37°C for overnight. The third was extraction of peptides from the gel slices. The gel slices were centrifuged briefly, and the aquatic extract supernatant was collected into a 0.5-mL Eppendorf tube. To the gel pieces, a 30-*μ*L volume of 0.1% formic acid (v/v, Burdic & Jacson) in 25-mM NH~4~HCO~3~ was added, followed by vortexing for 15 min and spinning briefly. The supernatant was harvested and pooled into the aquatic extract supernatant. The collected samples were then spun in a speed-vacuum to reduce the volume to approximately 10 *μ*L (avoid complete dryness). The samples were stored at −20°C. Lastly, capillary liquid chromatography-tandem mass spectrometry (LC/MS/MS) was conducted at the RCMI Proteomics & Protein Biomarkers Cores to determine the peptides derived from the proteins in the gel slices. Capillary LC/MS/MS was performed with a linear ion trap tandem mass spectrometer (LTQ-XLS, ThermoFisher), where the top 7 eluting ions were fragmented by collision-induced dissociation.

Proteins were identified by searching MS/MS spectra against the NCBI nonredundant protein database (version 20100306; 10551781 sequences and 3596151245 residues). A probability-based database searching algorithm (Mascot, Matrixscience) was followed as described previously \[[@B79]\] with modifications. Briefly, database search criteria include taxonomy, bacteria (eubacteria, 3035644 sequences); enzyme, trypsin; variable modifications, carbamidomethylation of cysteines and oxidation of methionines; mass values, monoisotopic; protein mass, unrestricted; peptide mass tolerance, ±1000 ppm; fragment mass tolerance, ±0.8 Da; max missed cleavages, three instrument type, ESI-TRAP; number of queries, 87976. Peptide score distribution: Ions score is −10 log (*P*), where *P* is the probability that the observed match is a random event.

With the molecular weight search (MOWSE) peptide-mass database developed \[[@B61]\], the MOWSE scoring algorithm was used to calculate a score of each peptide entry. Briefly, the experimental mass values were searched across a calculated peptide mass database. Match of experimental mass values with calculated values were counted when the calculated value was in the range of a given mass tolerance of an experimental value. These matches were probability (*P*) based to ensure that the observed match is a random event. In a search for such random matches, the significance threshold was set for *P* to be ≤0.05, that is, a 1 in 20 chance of being a false positive. The matches were scored, based on the calculated *P*, that is, −10 log (*P*). The higher the score, the lower the *P* value. These ions scores were used to calculate protein score, which was the sum of the highest ions score for each distinct sequence. The proteins that were consistently detected in the replicates were counted. The inferred proteins were further categorized for functions and domains in amino acid sequences with the protein analysis software and with the published data. Functions and amino acid sequences were inferred by using <http://www.uniprot.org/uniprot/O67077>. Proteins with signal peptide were searched with <http://www.signalpeptide.de/index.php?m=myproteinindex>. Signal peptide in the proteins was predicted by using <http://www.cbs.dtu.dk/services/SignalP/>. Transmembrane domains were deduced with <http://www.ch.embnet.org/software/TMPRED_form.html>.

3. Results {#sec3}
==========

3.1. Vesiculation Under Ciprofloxacin-Triggered SOS {#sec3.1}
---------------------------------------------------

The hypothesis concerning association of SOS with vesiculation was tested. The *P. aeruginosa*wild-type and the LexA noncleavable (*lexAN*) strains were treated with ciprofloxacin at 1 *μ*g/mL. OMVs were extracted from these strains. The rationale for the antibiotic treatment was that this antibiotic was known to activate the SOS response in *P. aeruginosa*at 1 *μ*g/mL, but SOS was noninducible in the *lexAN* strain \[[@B10]\]. Thus, testing of these strains with this drug would provide data relevant to SOS. When treated with the antibiotic, the wild-type cells became more filamented (cell length: 5.1 *μ*m ± 1.2 and *n* = 169) than the *lexAN* cells (4.61 *μ*m ± 1.2 and *n* = 89) (Figures [2(b)](#fig2){ref-type="fig"} and [2(e)](#fig2){ref-type="fig"}, *P* \< 0.0001). The significant cell filamentation is the manifestation of the SOS response \[[@B28], [@B27]--[@B49]\]. It is impossible to complement the *lexAN* mutant, because the *lexAN* phenotype is dominant; that is, in the *lexAN* background, the wild-type LexA would be cleaved, while the *lexAN* would remain not degraded during SOS. Besides, when both the wild-type and the *lexAN* cells were treated with ciprofloxacin at 1 *μ*g/mL, lysed cells appeared imperceptible (\<2%, *n* = 500), in contrast to treatment at 5 *μ*g/mL (minimal bactericidal concentration, MBC = 3.25 *μ*g/mL) that led to noticeable damaged and lysed cells (20%--30%, Figures [2(c)](#fig2){ref-type="fig"} and [2(f)](#fig2){ref-type="fig"}). With the growth conditions determined, OMVs were isolated by ultracentrifugation from the cell-free supernatants of the wild-type and the *lexAN* cultures shown in Figures [2(b)](#fig2){ref-type="fig"} and [2(e)](#fig2){ref-type="fig"}. The presence of OMVs in the samples was confirmed with transmission electron microscopy (Figures [2(b)](#fig2){ref-type="fig"} and [2(e)](#fig2){ref-type="fig"} insets). The diameters of OMVs from both strains appeared similar (*P* = 0.2 and *n* = 70). Additionally, phage activity was not detected in the 1-*μ*g/mL-drug-treated cell-free cultures and the OMV samples (data not shown). Hence, when the cells grew with the antibiotic at 1 *μ*g/mL and produced OMVs, the likelihood of OMV contamination with the unrelated proteins from lysed cells appeared very small and was further addressed as below.

3.2. Increase in OMV Protein Levels under SOS {#sec3.2}
---------------------------------------------

OMVs were quantified from the wild-type and the *lexAN* strains treated with ciprofloxacin at 1 *μ*g/mL. Briefly, both the wild-type and LexA noncleavable strains were grown with ciprofloxacin at 1 *μ*g/mL. Both strains exhibited similar growth behaviors in the absence and in the presence of ciprofloxacin ([Figure 3(a)](#fig3){ref-type="fig"}). Since OMV protein quantity appeared to reflect the levels of OMVs \[[@B69]\], the OMV levels were determined from the same volume of culture containing the equal number of cells ([Figure 3(a)](#fig3){ref-type="fig"} at 480 min) by using Bradford assay of OMV proteins. With the ciprofloxacin treatment, the level of the wild-type OMV proteins increased more than 100-fold, as compared to that without (\**P* \< 0.0001, [Figure 3(a)](#fig3){ref-type="fig"}). While the level of OMV proteins from the treated *lexAN* strain went up versus that of the untreated (*P* \< 0.01), it did not reach the wild-type level, displaying 33% reduction reproducibly below the wild-type level (\**P* \< 0.05, [Figure 3(a)](#fig3){ref-type="fig"}). These results demonstrate that vesiculation is stimulated by the antibiotic treatment. The data with *lexAN* suggest that the stimulation is attributed by LexA-dependent and independent mechanisms. The LexA-dependent mechanism of OMV stimulation involves SOS. The OMV protein level in the wild-type strain, which increased above that of the *lexAN* strain, was suppressed in the *lexAN* strain. Namely, the levels were increased when the SOS repressor LexA was autocleaved in the wild-type strain during SOS \[[@B47]\], but when LexA was made noncleavable in the *lexAN* strain \[[@B10]\], further augmentation appeared to cease. Therefore, these OMV proteins increased in the wild type but suppressed in the *lexAN* strain were termed the SOS-related. The LexA-independent mechanism may account for the increased levels of OMV proteins from the *lexAN* mutant over those from the untreated. These proteins were accordingly termed the SOS independent. Yet, the level was lower than that of the SOS-induced wild type ([Figure 3(a)](#fig3){ref-type="fig"}). In conclusion, the OMV protein level is increased from the cells treated with the antibiotic, and SOS contributes to the additional augmentation.

3.3. Increase in OMV Lipid Levels under SOS {#sec3.3}
-------------------------------------------

It seemed possible that the proteins unrelated to OMVs but produced during SOS might be co-centrifuged with OMVs. This possibility was excluded by OMV lipid quantification. From OMV protein quantification, given the observation that the increase in the OMV protein level in the treated wild-type strain was suppressed in the treated *lexAN* strain ([Figure 3(a)](#fig3){ref-type="fig"}), we wanted to confirm the increase in vesiculation with the lipid assay. The lipids were extracted from OMVs and cells, and the total dry lipids were weighed as described previously \[[@B2]\]. The OMV lipids of the wild-type strain treated with ciprofloxacin were heavier than those of the *lexAN* strain (\**P* \< 0.05, [Figure 3(b)](#fig3){ref-type="fig"}). In contrast, the weights of the total lipids from cells did not change significantly, irrespective of strains and treatment (*P* ≥ 0.1, data not shown). Thus, the OMV lipid mass increased for the treated wild type, and the augmentation was suppressed in the treated *lexAN* strain, the results consistent with the OMV protein quantification. This consistency ruled out the possibility of OMV contamination with unrelated proteins but supported the notion of SOS involvement in vesiculation, yet, the SOS-unrelated factors contributing to the increase cannot be excluded.

3.4. OMV-Mediated Macrophage Cytotoxicity under SOS {#sec3.4}
---------------------------------------------------

Since OMVs act as a virulence factor \[[@B6], [@B23]\] and the OMV levels increase during the antibiotic-induced SOS, we wanted to investigate whether OMVs from the SOS strains differentially aggravates cytotoxicity. OMVs isolated from the wild-type and the *lexAN* cultures, either treated as above with ciprofloxacin or without, were added to macrophage in equal amounts. The cytotoxicity was assessed as described previously \[[@B73]\]. First, macrophage morphology was examined after incubation with OMVs from the untreated wild-type bacterial cells for 0.5, 1, 2, 4, and 24 h. Morphology changes appeared in the first h ([Figure 4](#fig4){ref-type="fig"} Upper). OMVs from the ciprofloxacin-treated wild-type and the mutant cells caused dramatic alterations in the morphology of the macrophage, including cell shrinkage, detachment, and lysis, when compared with OMVs from the untreated bacterial cells. In contrast, treatment of macrophage with ciprofloxacin at 1 *μ*g/mL did not cause the cytotoxic morphology, the result excluding a possibility of ciprofloxacin-inflicted toxicity presumably caused by the drug-carrying OMVs. Second, the cytotoxicity was quantified. It is defined as the percentage of the OMV-inflicted LDH release from macrophage in the detergent-lysed maximal release from macrophage (OMVs or macrophage alone did not lead to a LDH-increase). As shown in [Figure 4](#fig4){ref-type="fig"} (lower), the OMV-inflicted macrophage toxicity appeared concentration-dependent. Cytotoxicity by OMVs from the treated wild-type strain increased over 55% versus that by OMVs from the untreated (*P* \< 0.05). These results indicate that the OMV-mediated cytotoxicity is stimulated by OMVs from the antibiotic-treated bacterial cells. However, this stimulated cytotoxicity was not observed in OMVs from the treated *lexAN* culture (*P* \< 0.05). Therefore, LexA appeared to suppress the increased cytotoxicity.

3.5. OMV Subproteomic Analysis {#sec3.5}
------------------------------

Under the ciprofloxacin treatment, the increased levels of the OMV proteins, lipids and the OMV-mediated cytotoxicity in the wild-type strain appeared to be suppressed in the *lexAN* strain. Many interesting questions were raised from these results as to what OMV proteins would be LexA-suppressed and what would be cytotoxicity-related. To address them, we examined the OMV subproteomes from the treated wild-type and the *lexAN* strains. The rationale for targeting the two treated strains was the following. For the treated wild-type strains, the OMV protein level was increased but suppressed for the *lexAN* strain. Thus, comparison of the OMV subproteomic data obtained from the two treated strains would provide information relevant to LexA or SOS. The comparison could help sort out the OMV proteins: the LexA-related and ciprofloxacin-specific or SOS-unrelated OMV proteins. When bacteria are treated with a certain antibiotic, drug-specific proteins were previously observed, such as OMPs \[[@B62], [@B81]\] and OMV proteins \[[@B35]\], which are unrelated to SOS. Most likely, the ciprofloxacin-specific OMV proteins would be found in both the wild-type and the *lexAN* OMV subproteomes, whereas the LexA-related OMV proteins would be detected in the OMV subproteome of the wild-type strain where LexA is autocleaved.

Experimentally, the OMV proteins from the antibiotic-treated wild-type and *lexAN* strains were characterized by the SDS-PAGE-based proteomic analysis ([Figure 5](#fig5){ref-type="fig"}). While small differences were observed in the OMV protein profiles for the treated wild-type and the *lexAN* strains ([Figure 5](#fig5){ref-type="fig"}), subtle distinctions were expected, based on LexA repression of gene expression, especially of the SOS regulons \[[@B13]--[@B10]\]. To unveil the differences, the *in vitro* trypsin proteolysis and capillary LC/MS/MS analysis was performed to determine the OMV proteins in the gel slices ([Figure 5](#fig5){ref-type="fig"}). The degraded peptide masses were determined and searched across the bacterial protein databases with the *P* \< 0.05-based MOWSE scoring algorithm \[[@B61]\]. Totally, 145 proteins were identified in the OMV subproteomes from the treated wild-type and the *lexAN* strains (Tables [1](#tab1){ref-type="table"}--[3](#tab3){ref-type="table"}). Many of the known OMV proteins, such as OstA (no. 1) \[[@B57]\] and OprE (no. 37) \[[@B3], [@B9]\], were detected in the wild-type OMVs ([Figure 5](#fig5){ref-type="fig"} and [Table 1](#tab1){ref-type="table"}), whereas GroEL (no. 75) \[[@B25]\] and OprF (no. 78) \[[@B3], [@B9]\] in both the wild-type and the *lexAN* OMVs ([Table 2](#tab2){ref-type="table"}). Thus, the OMV subproteomes were confirmed to harbor some known OMV proteins. Moreover, with the SOS status of the wild-type and the *lexAN* strains used, the subproteomic analyses led to discovery and categorization of SOS- and cytotoxicity-related OMV proteins. The proteins detected only in OMVs from the drug-treated wild-type cells were termed the WT OMV proteins (74 proteins listed in [Table 1](#tab1){ref-type="table"} or 51% of 145). Since SOS was triggered in the wild type but repressed in the *lexAN* strain \[[@B10]\], the proteins produced during SOS were expected to emerge in the wild-type OMVs but not in the *lexAN* OMVs. These proteins were SOS-related. However, the proteins present in OMVs from both the treated wild-type and the *lexAN* strains were named the common OMV proteins (35 in [Table 2](#tab2){ref-type="table"} or 24%). The presence in both the OMV subproteomes implied that the appearance in OMVs was not affected by LexA; thus these proteins were called the SOS-unrelated. The OMV proteins present in OMVs from the *lexAN* cells alone were called the *lexAN* OMV proteins (36 in [Table 3](#tab3){ref-type="table"} or 26%). While the categorization provides insights into the antibiotic-stimulated vesiculation, it does not seem reconciled with the protein banding profiles that show slight differences in OMV proteins from the wild-type and the *lexAN* strains. The apparent discrepancy stems from the limited capacity of SDS-PAGE in resolving proteins with similar sizes in a certain band and inability to separate proteins of similar masses but of different pIs. For instance, when parallel bands in the wild-type and the *lexAN* OMV proteins were cut off for proteomic analysis, the subproteomic contents of the proteins carrying various pIs in one band were not completely identical to those in its counterpart (data not shown). Obviously, the OMV subproteomic analysis appears comprehensive, remedying the limitation of SDS-PAGE analysis.

Interestingly, the OMV subproteomes seem to reflect the physiology of the cells under the antibiotic treatment and the cytotoxicity of OMVs to host cells. For instance, the known SOS-regulated proteins, such as FtsK (no. 41) \[[@B77]\] and catalase (no. 22) \[[@B33]\], were detected in the OMVs from the treated wild-type cells where SOS is induced. Proteins of efflux (no. 17) and cell motility (nos. 3, 34, and 42) were also found. Since efflux and cell mobility are involved in antibiotic resistance \[[@B60], [@B63]\], the presence of the related proteins in OMVs is likely to result from a response of the bacterial cells to the ciprofloxacin treatment. Furthermore, virulent proteins were detected in OMVs. In fact, cell mobility as mentioned above is known to enhance production of virulence factors \[[@B60]\]. An example in the WT OMV proteins is M48 family peptidase (no. 16 in [Table 1](#tab1){ref-type="table"}) that contains *Pseudomonas* metalloproteases, elastase, and alkaline protease. These proteins are believed to mediate tissue penetration \[[@B14]--[@B72]\]. The examples in the common category include cytochrome c (no. 84 in [Table 2](#tab2){ref-type="table"}) cytotoxic to macrophage \[[@B82]\], and OprG (no. 82) contributing to cytotoxicity toward human bronchial epithelial cells \[[@B54]\]. Examples in the *lexAN* group are the following: ATP-utilizing enzymes such as ATPase (no. 120 of [Table 3](#tab3){ref-type="table"}) cytotoxic to macrophage \[[@B82]\] and the LysM domain carrying protein (no. 118) involved in pathogenesis \[[@B7]\]. Taken together, the OMV subproteomic results appeared aligned with the functional results pertinent to drug resistance, SOS, and cytotoxicity.

4. Discussion {#sec4}
=============

Vesiculation from *P. aeruginosa* under ciprofloxacin treatment was investigated with multiple approaches. OMVs were isolated from the wild-type strain in which SOS is induced by ciprofloxacin and from the *lexAN* strain in which SOS is repressed. Cell morphology after the treatment showed cell filamentation, confirming SOS, while OMVs were not changed significantly in size during SOS. Vesiculation as determined chemically by the OMV protein and lipid levels and functionally by cytotoxicity is stimulated by the drug treatment, higher in the wild-type strain but suppressed in the *lexAN* strain. The overall increases for the wild-type and the *lexAN* strains suggest that the stimulation is attributed by the SOS-related and the independent factors; the suppression of further increase in the *lexAN* strain suggests that the additional augmentation involves SOS. The cytotoxicity of OMVs and the bacterial physiology under the antibiotic treatment and SOS were reflected by the results of the OMV subproteomic analysis.

An intriguing observation is the presence of cytosolic proteins in OMVs. Considering the hydrophobic nature of outer membrane, we were tempted to suspect contamination of OMVs with the cytosolic proteins. Nevertheless, the presence of the cytosolic proteins in OMVs is not just coincidental but consistently documented \[[@B45]\]. In fact, GroEL (no. 75), ribosomal proteins (nos. 76, 121, and 124), and DNA binding proteins (no. 96, 115) were detected in outer membrane \[[@B25], [@B17]--[@B43]\] and OMV fractions \[[@B25], [@B16]\]. The possible mechanisms for their OMV inclusion may involve association of the cytoplasmic proteins with membrane proteins that may bring the former to membrane proximity. For example, peptidyl-prolyl *cis-trans* isomerase, a membrane-associated protein (no. 95 in [Table 2](#tab2){ref-type="table"}), is a trigger factor that is highly conserved in most bacteria \[[@B30], [@B50]\]. The presence of the trigger factor in the stressed cells is reasonable as the trigger factor is generally believed to play a central role in bacterial survival of environmental insult. Since the trigger factor in *E. coli* is associated with the 50S ribosomal subunit \[[@B74]\] and GroEL \[[@B36]--[@B38]\], the factor is likely to be translocated with 50S ribosomal protein L28 and GroEL to OMVs. Besides, because OMVs can package DNA \[[@B35], [@B42]\] and *P. aeruginosa* OMVs carry DNA \[[@B64]\], the DNA binding proteins, such as DNA-binding stress protein (no. 115) and DNA-methyltransferase (no. 96), may be delivered into OMVs through hitching onto DNA.

The molecular mechanisms behind the vesiculation stimulation during SOS remain poorly understood. OMVs are generated from living cells by budding from outer membrane bulges with subsequent fission \[[@B4], [@B51], [@B35], [@B42], [@B46]\]. Vesiculation does not concur with cell lysis, for OMVs package newly synthesized proteins \[[@B52]--[@B83]\]. These may be the reasons that OMV yields were too low when ciprofloxacin was used at and above MBC (data not shown), but the OMV levels were high when the drug was administered at 1 *μ*g/mL. Therefore, the increase in the OMV protein levels observed in this work from the cultures treated with ciprofloxacin at 1 *μ*g/mL is unlikely to result from cell lysis, especially as lysed cells barely were observed in the culture treated with the drug. The OMV protein levels are most likely to reflect the vesiculation stimulation during SOS. Indeed, the SOS-induced vesiculation is corroborated by the OMV lipid quantification. The OMV induction can be interpreted by combination of cell division delay and envelope alteration incurred in SOS. During SOS, *sulA* is induced, whose product inhibits and delays cell division transiently until DNA damage is ameliorated. In *E. coli,*this is achieved by SulA binding to FtsZ to block septum formation \[[@B34], [@B49], [@B31], [@B71]\]; similarly, a complex of *P. aeruginosa* SulA with FtsZ has been reported \[[@B11]\]. Inhibition of cell division was observed in *P. aeruginosa* treated with ciprofloxacin ([Figure 2](#fig2){ref-type="fig"}). According to the model of OMV biogenesis \[[@B18]\], such an episode of division inhibition may invoke temporary impact on the envelope structure, stimulating OMV generation.

Our finding of vesiculation stimulation during SOS is highly significant. On one hand, suppression of the SOS-repair network by LexA in *E. coli* with engineered bacteriophage increased bactericidal effects of SOS-inducing antibiotics *in vitro* and enhanced survival of infected mice *in vivo*\[[@B48]\], paving a way for the LexA-based therapeutic strategy. In parallel are our results that LexA represses OMV stimulation and cytotoxicity, yet the *lexAN*-based strategy fails to eliminate them (Figures [3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}), pointing to existence of LexA independent mechanisms. The OMV protein levels increased in the cultures of the ciprofloxacin-treated *lexAN* mutant; the noncleavable LexA even appeared to contribute to production of some OMV proteins ([Figure 3(a)](#fig3){ref-type="fig"} and [Table 3](#tab3){ref-type="table"}). The observations lead to the SOS-independent mechanisms that demand future endeavor in investigation. On the other hand, SOS appears responsible for the antibiotic inducible-biofilm formation \[[@B28], [@B27]\] and vesiculation though the mechanisms behind the induction seem a mystery. Our data obtained with the OMV protein-, the lipid-, the cell- and the proteomic-based approaches suggest that SOS plays a role in the antibiotic-stimulated vesiculation and in OMV-mediated cytotoxicity to macrophage. The result may help develop guidelines for antibiotic practice to prevent such side effects as vesiculation and the related cytotoxicity to host defense cells.
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![The bacterial SOS response. The response is triggered by DNA-damage antibiotics. This response is controlled by the RecA-LexA interplay, in which LexA represses the SOS genes. DNA damage activates RecA to simulate autocatalytic cleavage of LexA so that the SOS genes are depressed and expressed. X, the mutation rendering LexA noncleavable.](TSWJ2012-402919.001){#fig1}

![Microscopy of *P. aeruginosa*under the ciprofloxacininduced SOS response. The wild-type (PAO1) and the LexA noncleavable (*lexAN*) strains were grown in LB with shaking for 2 hrs, and then ciprofloxacin (CPX) was added (1 *μ*g/mL). The culture continued for 6 hrs. (a) PAO1 without and (b) with CPX. (c) PAO1 with 5 *μ*g/mL CPX. (d) *lexAN*without and (e) with CPX. (f) *lexAN* with 5 *μ*g/mL CPX. Arrows in (c) and (f) show damaged and lysed cells. Cell bar, 5 *μ*m. Inset (b) shows transmission electron microscopy of OMVs from the treated wild-type cultures. Inset (e) shows *lexAN*OMVs. OMV bar, 0.1 *μ*m.](TSWJ2012-402919.002){#fig2}

![OMV production from *P. aeruginosa*under the ciprofloxacin-induced SOS response. (a) Growth of the wild-type (PAO1) and the LexA noncleavable strains. Both strain were grown in LB with shaking for 2 hrs, and then ciprofloxacin (CPX) was added. The culture continued for 6 hrs. OMVs were isolated from the wild-type and the *lexAN*cells treated with or without ciprofloxacin (CPX). (b) Quantification of OMV proteins by Bradford (*n* = 7) and (c) OMV lipids by weight (*n* = 3). (\**P* \< 0.05).](TSWJ2012-402919.003){#fig3}

![OMV-mediated macrophage cytotoxicity is SOS dependant. OMVs isolated from the wild-type (wt) and the LexA noncleavable (*lexAN*) cells as indicated were incubated with macrophage. Top: phase-contrast microscopy of macrophage incubated with OMVs at 1.3 *μ*g/mL after a 1 hr incubation. Bar, 20 *μ*m. Bottom: cytotoxicity was measured as the levels of released cytosolic lactate dehydrogenase after 4 hr incubation. It was set 0 for the macrophage-only control. OMV concentrations: grey, 1.3 *μ*g/mL; doted, 0.65 *μ*g/mL; blank, 0.325 *μ*g/mL. (\**P* \< 0.05, *n* = 4).](TSWJ2012-402919.004){#fig4}

![The SDS-PAGE based proteomic analyses of OMV proteins from the SOS-induced and the un-induced cells. CPX, ciprofloxacin. N, LexA noncleavable; and wt, wild-type. Illustrated to the right were the proteins known to associate with OMVs, cytotoxicity, and SOS (See text and Tables for details).](TSWJ2012-402919.005){#fig5}

###### 

The WT OMV proteins.

  Protein access ID     Protein description                                                                                          Score   pI      Mass     Predicted functions                                   Membrane domains
  --------------------- ------------------------------------------------------------------------------------------------------------ ------- ------- -------- ----------------------------------------------------- ------------------
  \(1\) gi∣15595792     OstA precursor \[*P. aeruginosa*PAO1\]                                                                       366     5.41    104207   Organic solvent tolerance protein                     SP, TM
  \(2\) gi∣30525581     ChaPs, heat-shock protein \[*Piscirickettsia salmonis*\]                                                     174     4.79    57310    Protein folding, immunogenic protein                  n, TM
  \(3\) gi∣15595608     PilJ \[*P. aeruginosa* PAO1\]                                                                                165     4.65    72484    Cell motility, twitching motility                     SP, TM
  \(4\) gi∣15597641     Glycine dehydrogenase \[*P. aeruginosa* PAO1\]                                                               133     5.68    103853   Degradation of glycine                                n, TM
  \(5\) gi∣254236694    OprC precursor, putative \[*P. aeruginosa* C3719\]                                                           117     6.02    79268    Copper transport outer membrane porin                 SP, TM
  \(6\) gi∣15599015     SecF \[*P. aeruginosa*PAO1\]                                                                                 115     4.81    33021    Protein translocation                                 SP, TM
  \(7\) gi∣15599417     Fe(III)-pyochelin OM receptor precursor \[*P. aeruginosa*PAO1\]                                              107     5.86    79943    Siderophore-iron transmembrane transporter activity   SP, TM
  \(8\) gi∣309885       Aspartate transcarbamoylase \[*P. aeruginosa* PAO1\]                                                         102     6.17    36521    Pyrimidine biosynthesis                               n, n
  \(9\) gi∣83718562     Peptide synthetase-like protein \[*Burkholderia thailandensis*E264\]                                         96      5.91    349402   Peptide synthesis                                     n, TM
  \(10\) gi∣152986344   YaeT \[*P. aeruginosa*PA7\]                                                                                  94      5.02    88222    OMP assembly complex                                  SP, TM
  \(11\) gi∣124022818   Phosphate binding protein \[*Prochlorococcus marinus* str. MIT 9303\]                                        90      9.51    18989    ABC transport                                         SP, TM
  \(12\) gi∣167840097   Phospholipase D \[*Burkholderia thailandensis* MSMB43\]                                                      88      6       64431    Lipid catalytic activity                              n, TM
  \(13\) gi∣167035883   TonB-dependent copper receptor \[*P. putida* GB-1\]                                                          87      5.77    74399    Copper receptor                                       SP, TM
  \(14\) gi∣28871621    Polyribonucleotide nucleotidyltransferase \[*P. syringae pv. tomato* str. DC3000\]                           81      5.20    74880    mRNA degradation                                      n, TM
  \(15\) gi∣15600748    ATP synthase subunit *γ* \[*P. aeruginosa* PAO1\]                                                            73      7.70    31533    ATP production                                        n,n
  \(16\) gi∣70732441    M48 family peptidase \[*P. fluorescens*Pf-5\]                                                                69      7.66    28833    Protein dagradation                                   SP, TM
  \(17\) gi∣50085971    Acridine efflux pump \[*Acinetobacter*sp. ADP1\]                                                             67      6.36    114705   Efflux pump                                           n, TM
  \(18\) gi∣15596751    Cytochrome oxidase subunit (cbb3-type) \[*P. aeruginosa*PAO1\]                                               66      9.42    53073    Electron transport chain                              n, TM
  \(19\) gi∣119713613   SecD \[uncultured marine bacterium EB0_39H12\]                                                               62      5.63    67763    Protein translocation                                 n, TM
  \(20\) gi∣7715581     PspA \[*Streptococcus pneumoniae*\]                                                                          61      4.70    27305    Pneumococcal surface protein A                        n, n
  \(21\) gi∣10945103    PapA \[*P. aeruginosa*\]                                                                                     61      4.87    71649    Lipid metabolic process                               SP, TM
  \(22\) gi∣121605556   Catalase \[*Polaromonas naphthalenivorans*CJ2\]                                                              61      6.26    54212    Hydrogen peroxide catabolic process                   n, n
  \(23\) gi∣94495248    Rhizopine catabolism protein \[*Sphingomonas* sp. SKA58\]                                                    60      5.91    38825    Oxidation reduction                                   n, TM
  \(24\) gi∣116328093   Zn-dependent hydrolase \[*Leptospira borgpetersenii* serovar Hardjo-bovis L550\]                             59      5.67    30997    Hydrolase activity                                    SP, TM
  \(25\) gi∣149378317   PAS \[*Marinobacter algicola* DG893\]                                                                        59      5.97    57059    Signal transducer activity, chemotaxis                TM
  \(26\) gi∣119356290   Molybdate ABC transporter, ATPase subunit \[*Chlorobium phaeobacteroides* DSM 266\]                          59      9.23    38876    ABC transport                                         n, n
  \(27\) gi∣117619653   Methyl-accepting chemotaxis transducer \[*P. stutzeri* A1501\]                                               59      4.67    58670    Methyl-accepting chemotaxis                           SP, TM
  \(28\) gi∣119899764   MCP-domain-containing signal transduction protein \[*Azoarcus* sp. BH72\]                                    59      5.80    53615    Signal transduction                                   SP, TM
  \(29\) gi∣887858      DcrH \[*Desulfovibrio vulgaris* str. Hildenborough\]                                                         59      5.71    104664   Signal transduction                                   SP, TM
  \(30\) gi∣28869218    Aerotaxis receptor \[*P. syringae* pv. tomato str. DC3000\]                                                  59      5.70    56965    Aerotaxis                                             n, TM
  \(31\) gi∣112004994   Symbionin \[*Buchnera aphidicola*\]                                                                          58      5.13    57904    Protein folding                                       n, TM
  \(32\) gi∣15597430    PslD, biofilm proteins \[*P. aeruginosa PAO1*\]                                                              58      8.66    27891    polysaccharide transmembrane transport                SP, TM
  \(33\) gi∣154253615   Molybdenum cofactor biosynthesis protein C \[*Parvibaculum lavamentivorans*DS-1\]                            58      9.64    16871    Cofactor biosynthesis                                 n, n
  \(34\) gi∣15600235    PilO \[*P. aeruginosa*PAO1\]                                                                                 57      5.04    22805    Cell motility, type 4 fimbrial biogenesis             n, TM
  \(35\) gi∣29830660    Oxidoreductase \[*Streptomyces avermitilis* MA-4680\]                                                        57      5.01    33162    Electron transport chain                              n, TM
  \(36\) gi∣108803685   Bifunctional homocysteine S-methyltransferase \[*Rubrobacter xylanophilus* DSM 9941\]                        57      6.33    65183    Amino-acid biosynthesis                               n, TM
  \(37\) gi∣15595488    OprE precursor \[*P. aeruginosa PAO1*\]                                                                      54      8.67    49637    Anaerobically-induced OM porin                        SP, TM
  \(38\) gi∣121997032   Glycolate oxidase iron-sulfur subunit \[*Halorhodospira halophila* SL1\]                                     53      8.55    43945    Oxidation reduction                                   n, n
  \(39\) gi∣161508096   Biotin-acetyl-CoA-carboxylase ligase \[*Lactobacillus helveticus* DPC 4571\]                                 53      9       37120    Protein modification process                          n, n
  \(40\) gi∣119773234   GTPase EngB \[*Shewanella amazonensis* SB2B\]                                                                52      6.97    24168    Cell division                                         n, n
  \(41\) gi∣75764772    FtsK \[*Bacillus thuringiensis*serovar israelensis ATCC 35646\]                                              50      4.33    40378    Cell division                                         SP, TM
  \(42\) gi∣3237312     FimV \[*P. aeruginosa* PAO1\]                                                                                50      4.33    98113    Cell motility, twitching motility                     SP, TM
  \(43\) gi∣145588417   Ferric uptake regulator family protein \[*Polynucleobacter necessarius* subsp. asymbioticus QLW-P1DMWA-1\]   50      6.29    17176    Repressor of the iron transport operon                n, n
  \(44\) gi∣163846285   Deoxyribose-phosphate aldolase \[*Chloroflexus aurantiacus* J-10-fl\]                                        50      6.08    27440    Deoxyribonucleotide catabolic process                 n, n
  \(45\) gi∣107099581   Hypothetical+C448_01000594 \[*P. aeruginosa*PACS2\]                                                          267     5.13    101779   Unknown                                               Unknown
  \(46\) gi∣15598924    Hypothetical PA3729 \[*P. aeruginosa PAO1*\]                                                                 249     5.18    75836    Unknown                                               n, TM
  \(47\) gi∣15599685    Hypothetical PA4489 \[*P. aeruginosa PAO1*\]                                                                 179     5.48    167326   Putative endopeptidase inhibitor activity             SP, TM
  \(48\) gi∣156932378   Hypothetical ESA_00154 \[Enterobacter sakazakii ATCC BAA-894\]                                               167     4.83    57278    Protein folding                                       n, TM
  \(49\) gi∣15596261    Hypothetical PA1064 \[*P. aeruginosa*PAO1\]                                                                  116     5.38    24157    Unknown                                               n, TM
  \(50\) gi∣218890269   Hypothetical PLES_15291 \[*P. aeruginosa*LESB58\]                                                            97      6.34    28636    Unknown                                               SP, TM
  \(51\) gi∣15595825    Hypothetical PA0628 \[*P. aeruginosa*PAO1\]                                                                  92      8.80    35848    Unknown                                               n, n
  \(52\) gi∣15600425    Hypothetical PA5232 \[*P. aeruginosa* PAO1\]                                                                 90      9.11    38586    Protein transporter                                   SP, TM
  \(53\) gi∣15596143    Hypothetical PA0946 \[*P. aeruginosa* PAO1\]                                                                 86      4.93    36754    Unknown                                               SP, TM
  \(54\) gi∣107103341   Hypothetical PaerPA_01004410 \[*P*. aeruginosa PACS2\]                                                       84      9.02    67631    Unknown                                               Unknown
  \(55\) gi∣15599691    Hypothetical PA4495 \[*P. aeruginosa*PAO1\]                                                                  84      5.79    24864    Unknown                                               SP, TM
  \(56\) gi∣15600607    Hypothetical PA5414 \[*P. aeruginosa*PAO1\]                                                                  75      5.76    22533    Unknown                                               SP, TM
  \(57\) gi∣1162960     Protein homologous to HI0366 in Haemophilus influenzae \[*P. aeruginosa*PAO1\]                               72      6.77    22403    Unknown                                               SP, TM
  \(58\) gi∣148980343   Hypothetical VSWAT3_23674 \[*Vibrionales bacterium* SWAT-3\]                                                 59      4.85    56161    Chemotaxis                                            SP, TM
  \(59\) gi∣86146473    Hypothetical MED222_12698 \[*Vibrio* sp. MED222\]                                                            59      4.76    68870    Signal transducer activity                            n, TM
  \(60\) gi∣32266390    Hypothetical HH0891 \[*Helicobacter hepaticus*ATCC 51449\]                                                   59      4.99    52013    Signal transducer activity                            n, n
  \(61\) gi∣89893845    Hypothetical DSY1099 \[*Desulfitobacterium hafniense* Y51\]                                                  59      5.00    54148    Signal transducer activity                            n, n
  \(62\) gi∣18309647    Hypothetical CPE0665 \[*Clostridium perfringens*str. 13\]                                                    59      4.91    28888    Unknown                                               Unknown
  \(63\) gi∣160938898   Hypothetical CLOBOL_03792 \[*Clostridium bolteae* ATCC BAA-613\]                                             59      4.79    60828    Chemotaxis                                            SP, TM
  \(64\) gi∣167772543   Hypothetical ANACOL_03921 \[*Anaerotruncus colihominis* DSM 17241\]                                          59      4.66    71478    Signal transducer activity                            SP, TM
  \(65\) gi∣158334828   Hypothetical AM1_1665 \[*Acaryochloris marina* MBIC11017\]                                                   59      4.54    28589    Unknown                                               n, n
  \(66\) gi∣146298741   Hypothetical Fjoh_0980 \[*Flavobacterium johnsoniae* UW101\]                                                 58      8.90    168226   Unknown                                               SP, TM
  \(67\) gi∣126348240   Conserved hypothetical \[*Streptomyces ambofaciens* ATCC 23877\]                                             58      4.68    123551   Unknown                                               Unknown
  \(68\) gi∣162454210   Hypothetical sce5933 \[*Sorangium cellulosum* So ce 56\]                                                     56      10.06   49450    Unknown                                               SP, TM
  \(69\) gi∣159184340   Hypothetical Atu0493 \[*Agrobacterium tumefaciens* str. C58\]                                                56      8.83    17570    Unknown                                               Unknown
  \(70\) gi∣120536835   Hypothetical Maqu_4123 \[*Marinobacter aquaeolei* VT8\]                                                      54      6.02    36805    Unknown                                               n, n
  \(71\) gi∣88800650    Hypothetical MED297_05259 \[*Reinekea* sp. MED297\]                                                          53      5.05    74044    Unknown                                               Unknown
  \(72\) gi∣107103648   Hypothetical PaerPA_01004718 \[*P. aeruginosa* PACS2\]                                                       52      8.92    52714    Unknown                                               Unknown
  \(73\) gi∣124385398   Hypothetical BMA10229_A0995 \[*Burkholderia mallei* NCTC 10229\]                                             52      5.66    5192     Unknown                                               n, n
  \(74\) gi∣94986987    Hypothetical LI0545 \[*Lawsonia intracellularis*PHE/MN1-00\]                                                 51      6.43    11768    Unknown                                               n, n

TM: transmembrane domains; SP: signal peptide; pI: isoelectric point.

###### 

The common OMV proteins.

  Protein access ID      Protein description                                                                      Score   pI     Mass     Predicted functions                                                                                   Membrane domains
  ---------------------- ---------------------------------------------------------------------------------------- ------- ------ -------- ----------------------------------------------------------------------------------------------------- ------------------
  \(75\) gi∣576779       GroEL \[*P. aeruginosa*\]                                                                784     5.04   57036    Protein folding                                                                                       n, n
  \(76\) gi∣167855908    50S ribosomal protein L28 \[*Haemophilus parasuis* 29755\]                               242     4.90   57645    Protein synthesis                                                                                     n, n
  \(77\) gi∣15596780     Succinate dehydrogenase flavoprotein subunit \[*P. aeruginosa*PAO1\]                     175     6.04   63492    Tricarboxylic acid cycle                                                                              n, TM
  \(78\) gi∣15596974     OprF precursor \[*P. aeruginosa* PAO1\]                                                  166     4.98   37616    Major porin, ion transport                                                                            SP, TM
  \(79\) gi∣15596375     OprH precursor \[*P. aeruginosa* PAO1\]                                                  107     9.00   21561    Response to Mg^2+^ starvation                                                                         SP, TM
  \(80\) gi∣15598888     OMP precursor \[*P. aeruginosa* PAO1\]                                                   103     9.45   28497    OM                                                                                                    SP, TM
  \(81\) gi∣2626833      Chemotactic transducer \[*P. aeruginosa*PAO1\]                                           98      4.88   68395    Chemotaxis                                                                                            SP, TM
  \(82\) gi∣15599262     OprG precursor \[*P. aeruginosa* PAO1\]                                                  93      4.85   25178    OmpW family                                                                                           SP, TM
  \(83\) gi∣15598278     Glycine betaine transmethylase \[*P. aeruginosa* PAO1\]                                  74      4.74   71360    Utilization of choline and glycine betaine as carbon and nitrogen sources                             SP, TM
  \(84\) gi∣15596750     Cytochrome c oxidase subunit \[*P. aeruginosa* PAO1\]                                    74      7.79   22744    Electron carrier activity                                                                             n\. TM
  \(85\) gi∣37522034     Glycosyltransferase \[*Gloeobacter violaceus* PCC 7421\]                                 70      8.96   47611    Biosynthesis of glycoproteins                                                                         n, n
  \(86\) gi∣15596166     TolQ \[*P. aeruginosa* PAO1\]                                                            67      5.96   25266    Import of group A colicins for envelope integrity                                                     n, TM
  \(87\) gi∣15599941     SecG \[*P. aeruginosa* PAO1\]                                                            65      5.21   13199    Protein translocation                                                                                 n, TM
  \(88\) gi∣151545       RNA polymerase subunit \[*P. aeruginosa*\]                                               63      4.95   30372    RNA synthesis                                                                                         n, n
  \(89\) gi∣115523809    OmpA/MotB domain-containing protein \[*RhodoP. palustris* BisA53\]                       63      7.60   45685    Major nonspecific porin                                                                               SP, TM
  \(90\) gi∣114563330    Phosphoglucomutase \[*Shewanella frigidimarina* NCIMB 400\]                              62      5.39   62288    Carbohydrate metabolic process                                                                        n, n
  \(91\) gi∣15596170     OprL precursor \[*P. aeruginosa*PAO1\]                                                   61      5.95   17914    Peptidoglycan-associated OM lipoprotein                                                               SP, TM
  \(92\) gi∣15598193     Na(+)-translocating NADH-quinone reductase subunit C \[*P. aeruginosa* PAO1\]            61      5.67   27763    Reduction of ubiquinone-1 to ubiquinol and transport of Na^+^ ions                                    SP, TM
  \(93\) gi∣15598107     TonB-dependent receptor, putative \[*P. aeruginosa* PAO1\]                               60      6.24   80241    High-affinity binding and energy-dependent uptake of specific substrates into the periplasmic space   SP, TM
  \(94\) gi∣162455126    Protein kinase \[*Sorangium cellulosum* So ce 56\]                                       57      6.16   189825   Kinase activity                                                                                       n, n
  \(95\) gi∣15597002     Peptidyl-prolyl cis-trans isomerase D \[*P. aeruginosa* PAO1\]                           57      4.99   68699    Protein folding                                                                                       n, TM
  \(96\) gi∣183602700    Site-specific DNA-methyltransferase \[*Bifidobacterium animalis* subsp. lactis HN019\]   56      6.24   51123    DNA methylation                                                                                       n, n
  \(97\) gi∣15600134     HflC \[*P. aeruginosa* PAO1\]                                                            50      9.48   33095    Peptidase activity                                                                                    SP, TM
  \(98\) gi∣15599627     Iron-sulfur protein \[*P. aeruginosa* PAO1\]                                             50      6.07   20815    Iron-sulfur cluster assembly                                                                          n, n
  \(99\) gi∣15595268     Hypothetica PA0070 \[*P. aeruginosa* PAO1\]                                              114     8.93   31697    Unknown                                                                                               SP, TM
  \(100\) gi∣15596030    Hypothetica PA0833 \[*P. aeruginosa*PAO1\]                                               104     8.89   24698    OmpA family                                                                                           SP, TM
  \(101\) gi∣15597431    Hypothetica PA2235 \[*P. aeruginosa* PAO1\]                                              93      5.99   74519    Lipopolysaccharide biosynthetic process                                                               n, TM
  \(102\) gi∣15595823    Hypothetica PA0626 \[*P. aeruginosa* PAO1\]                                              87      9.67   31273    Unknown                                                                                               n, n
  \(103\) gi∣15599828    Hypothetica PA4632 \[*P. aeruginosa*PAO1\]                                               81      6.97   29141    Proteolysis                                                                                           SP, TM
  \(104\) gi∣15599183    Hypothetica PA3988 \[*P. aeruginosa* PAO1\]                                              67      5.23   22870    OM assembly                                                                                           SP, TM
  \(105\) gi∣152989513   Hypothetica PSPA7_0777 \[*P. aeruginosa* PA7\]                                           62      4.77   17484    Unknown                                                                                               n, n
  \(106\) gi∣15595830    Hypothetica PA0633 \[*P. aeruginosa*PAO1\]                                               62      4.93   17528    Unknown                                                                                               n, n
  \(107\) gi∣15595812    Hypothetica PA0615 \[*P. aeruginosa* PAO1\]                                              60      4.53   18939    Unknown                                                                                               n, n
  \(108\) gi∣15595813    Hypothetica PA0616 \[*P. aeruginosa* PAO1\]                                              58      5.93   19410    Unknown                                                                                               n, TM
  \(109\) gi∣15599619    Hypothetica PA4423 \[*P. aeruginosa* PAO1\]                                              51      6.69   65589    Unknown                                                                                               SP, TM

TM: transmembrane domains; SP: signal peptide. pI: isoelectric point.

###### 

The *lexAN* OMV proteins.

  Protein access ID      Protein description                                                                      Score   pI      Mass    Predicted functions                                           Membrane domains
  ---------------------- ---------------------------------------------------------------------------------------- ------- ------- ------- ------------------------------------------------------------- ------------------
  \(110\) gi∣15599248    6,7-dimethyl-8-ribityllumazine synthase \[*P. aeruginosa* PAO1\]                         299     5.69    16403   Riboflavin biosynthesis                                       n, n
  \(111\) gi∣14573303    PilA \[*P. aeruginosa*\]                                                                 160     6.23    15488   Major pilin subunit of type IV pili                           n, TM
  \(112\) gi∣15598049    OprI precursor \[*P. aeruginosa* PAO1\]                                                  132     7.90    8829    OM lipid-anchor.                                              SP, TM
  \(113\) gi∣15596004    AmpDh3 \[*P*. aeruginosa PAO1\]                                                          129     5.89    28703   Peptidoglycan catabolic process                               n, n
  \(114\) gi∣15599856    Lipid A 3-O-deacylase \[*P. aeruginosa* PAO1\]                                           116     5.87    18382   Modification of lipid A of LPS                                SP, TM
  \(115\) gi∣15596159    DNA-binding stress protein \[*P. aeruginosa* PAO1\]                                      100     4.96    17482   Response to stress, iron ion homeostasis                      n, n
  \(116\) gi∣15599000    PilF \[*P. aeruginosa* PAO1\]                                                            75      6.67    28520   Type 4 fimbrial biogenesis                                    SP, TM
  \(117\) gi∣15596133    LpxO2 \[*P. aeruginosa* PAO1\]                                                           72      9.90    35737   LPS biosynthesis                                              n, TM
  \(118\) gi∣15600371    LysM domain/BON superfamily protein \[*P. aeruginosa*PAO1\]                              69      5.45    15451   Cleavage of septal peptidoglycan to allow cell separation     n, n
  \(119\) gi∣15598026    HtpX \[*P. aeruginosa* PAO1\]                                                            65      7.03    31573   Heat shock protein, proteolysis                               SP, TM
  \(120\) gi∣15600018    Mg(2+) transport ATPase, P-type 2 \[*P. aeruginosa* PAO1\]                               63      5.88    99987   Magnesium-importing ATPase activity                           n, TM
  \(121\) gi∣15599764    50S ribosomal protein L21 \[*P. aeruginosa* PAO1\]                                       62      9.85    11646   Protein synthesis                                             n, n
  \(122\) gi∣116620118   HAD family hydrolase \[*Solibacter usitatus* Ellin6076\]                                 57      5.37    22870   Phosphoglycolate phosphatase activity                         n, n
  \(123\) gi∣21233204    RhlB \[*Xanthomonas campestris* pv. campestris str. ATCC 33913\]                         51      9.25    62279   ATP-dependent RNA helicase unwinding of double stranded RNA   n, n
  \(124\) gi∣15599463    30S ribosomal protein S7 \[*P. aeruginosa* PAO1\]                                        51      10.24   17493   Protein synthesis                                             n, n
  \(125\) gi∣73537822    Twin-arginine translocation pathway signal \[*Ralstonia eutropha* JMP134\]               50      9.37    36128   Protein export through the cytoplasmic membrane               SP, TM
  \(126\) gi∣71064880    GltI \[*Psychrobacter arcticus* 273-4\]                                                  50      5.11    35348   ABC glutamate/aspartate transporter                           SP, n
  \(127\) gi∣15596250    HypotheticalPA1053 \[*P. aeruginosa*PAO1\]                                               279     9.64    15639   Unknown                                                       SP, TM
  \(128\) gi∣15599835    HypotheticalPA4639 \[*P. aeruginosa* PAO1\]                                              98      9.47    20723   Unknown                                                       SP, TM
  \(129\) gi∣15600165    HypotheticalPA4972 \[*P. aeruginosa* PAO1\]                                              86      5.98    27836   Unknown                                                       SP, TM
  \(130\) gi∣15598227    HypotheticalPA3031 \[*P. aeruginosa*PAO1\]                                               83      4.92    8007    Unknown                                                       SP, TM
  \(131\) gi∣15598151    HypotheticalPA2955 \[*P. aeruginosa* PAO1\]                                              70      5.35    23677   Unknown                                                       SP, TM
  \(132\) gi∣145635820   HypotheticalCGSHiAA_01062 \[*Haemophilus influenzae* PittAA\]                            69      5.85    56041   Unknown                                                       n, n
  \(133\) gi∣183222376   Hypothetical LEPBI_I3030 \[*Leptospira biflexa serovar* Patoc strain Patoc 1 (Paris)\]   61      8.40    51147   Transporter activity                                          SP, TM
  \(134\) gi∣57233652    HypotheticalDET1586 \[*Dehalococcoides ethenogenes* 195\]                                61      8.80    21290   Unknown                                                       SP, TM
  \(135\) gi∣29377408    HypotheticalEF2944 \[*Enterococcus faecalis* V583\]                                      58      4.99    19312   Unknown                                                       n, n
  \(136\) gi∣15597823    HypotheticalPA2627 \[*P. aeruginosa*PAO1\]                                               57      10.35   23048   Unknown                                                       n, n
  \(137\) gi∣116750341   HypotheticalSfum_2918 \[*Syntrophobacter fumaroxidans* MPOB\]                            54      5.40    89798   Carbohydrate binding                                          SP, TM
  \(138\) gi∣167751139   Hypothetical EUBSIR_02124 \[*Eubacterium siraeum* DSM 15702\]                            53      5.50    44267   Metal ion binding                                             n, TM
  \(139\) gi∣26250264    Hypotheticalc4442 \[*E. coli* CFT073\]                                                   53      9.39    39090   Unknown                                                       n, TM
  \(140\) gi∣167754381   Hypothetical ALIPUT_02675 \[*Alistipes putredinis* DSM 17216\]                           53      6.89    18845   Methyltransferase activity                                    n, n
  \(141\) gi∣116048834   Hypothetical PA14_52490 \[*P. aeruginosa* UCBPP-PA14\]                                   52      6.19    17828   Unknown                                                       n, n
  \(142\) gi∣83312716    Hypothetical amb3617 \[*Magnetospirillum magneticum* AMB-1\]                             52      5.42    89219   Cyclic nucleotide biosynthetic process                        n, TM
  \(143\) gi∣154503183   Hypothetical RUMGNA_01007 \[*Ruminococcus gnavus* ATCC 29149\]                           51      5.29    49010   Rhamnose metabolic process                                    n, n
  \(144\) gi∣15598505    Hypothetical PA3309 \[*P. aeruginosa* PAO1\]                                             51      5.50    16486   Response to stress                                            n, n
  \(145\) gi∣148255416   HypotheticalBBta_4029 \[*Bradyrhizobium* sp. BTAi1\]                                     51      4.22    4004    Unknown                                                       n, n

TM: transmembrane domains; SP: signal peptide. pI: isoelectric point.
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